Biotech Firms Step Up Investment in Obesity and Oncology Drugs... What Will Drive Their Stock Prices?
Domestic biotech and pharmaceutical companies are expanding their R&D investments in obesity and oncology, seeking to secure new growth drivers. They are putting profits from existing products into developing new drug candidates and pursuing expansion into overseas markets. However, increased investment does not translate into profits immediately. Going forward, corporate value is expected to depend on the progress of clinical trials, the likelihood of regulatory approval, milestone payments received at each stage after technology out-licensing, and actual sales performance.
Investors using credit or margin trading while awaiting new-drug development results should keep an eye on both companies' development schedules and their own repayment deadlines. Repayment may come due before anticipated results are achieved, or a stock price adjustment may reduce the value of their collateral. Those considering refinancing to prepare for forced liquidation should compare which stocks are eligible for stock-backed loans, applicable interest rates, when refinancing is possible, and collateral maintenance requirements. By adjusting their funding plans to match their repayment capacity, they can keep track of companies' growth potential while also having options for responding to changes in their account status.
HiStockLoan has maintained its position as the industry leader for 22 years and offers a range of stock financing products, including products with annual interest rates in the 5% range. It can be used not only to secure new investment funds but also to manage funds by refinancing credit and margin transactions, making it an option attracting investors seeking to seize investment opportunities while reducing their funding burden.
[Visit HiStockLoan, the industry leader: https://www.hisl.co.kr]
Meanwhile, interest in stock-backed loans is growing by the day. Investors looking to seize investment opportunities when they arise are turning to stock-backed loans, which allow them to access more funds for stock purchases.
Another advantage of stock-backed loans is that even if investors using margin or credit trading face the risk of forced liquidation following a sharp drop in stock prices, they can switch to a stock-backed loan with ease, without adding collateral or selling stocks, and wait for a rebound.
HiStockLoan: Additional investment funds and refinancing of credit and margin trades, at industry-low interest rates in the 5% range per year!
HiStockLoan has launched a securities-linked credit product with industry-low interest rates in the 5% range per year, so investors can use stock-backed loans without undue burden. The product can be used both to purchase stocks and to refinance securities firms' margin or credit transactions. Investors can access up to four times their equity, including their own capital, regardless of credit rating. It is also available to investors using the alternative trading system (NXT). Recently, securities firms have shortened the term for new margin loans from 180 days to 90 days, so investors concerned about the length of time they can use funds may also wish to consider refinancing through a stock-backed loan.
Investors who would like to learn about HiStockLoan's range of tailored products can contact the customer service center at 1566-5113 for convenient consultations with a professional adviser, 24 hours a day, regardless of whether they qualify for a loan.
- Industry-low interest rate products in the 5% range per year
- ETF trading available
- No. 1 in market share for 22 consecutive years; winner of the Korea First Brand Awards for 17 consecutive years
- Real-time repayment of securities firms' margin and credit balances
- Trading available through the alternative trading system (NXT)
- Reliable consultation quality guarantee system
* HiStockLoan Customer Service Center: 1566-5113
Visit: https://www.hisl.co.kr
Samsung Electronics (Preferred), Seongho Electronics, SIMMTECH, AriBio Holdings, Celltrion
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
※ This content does not reflect the editorial direction of The Asia Business Daily. The information provider bears full responsibility for its contents.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.